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Abstract: Marine invertebrates are rich sources of bioactive compounds and their 
biotechnological potential attracts scientific and economic interest worldwide. Although 
sponges are the foremost providers of marine bioactive compounds, cnidarians are also 
being studied with promising results. This diverse group of marine invertebrates includes 
over 11,000 species, 7500 of them belonging to the class Anthozoa. We present an 
overview of some of the most promising marine bioactive compounds from a therapeutic 
point of view isolated from cnidarians in the first decade of the 21st century. Anthozoan 
orders Alcyonacea and Gorgonacea exhibit by far the highest number of species yielding 
promising compounds. Antitumor activity has been the major area of interest in the 
screening of cnidarian compounds, the most promising ones being terpenoids 
(monoterpenoids, diterpenoids, sesquiterpenoids). We also discuss the future of 
bioprospecting for new marine bioactive compounds produced by cnidarians. 
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1. Introduction 
In terms of biodiversity, marine environments are among the richest and most complex ecosystems. 
Harsh chemical and physical conditions in the environment have been important drivers for the 
production of a variety of molecules with unique structural features. These marine molecules exhibit 
various types of biological activities [1], with compounds of high economic interest having potential 
applications in the pharmaceutical and medical sectors. Although nearly 20,000 compounds have been 
discovered since the field of marine bioactive compound biochemistry began in the mid-1960s, only a 
very limited number have seen industrial application. It has been clear since marine bioprospecting 
began that the world’s oceans and their diverse biota represent a significant resource, perhaps the 
greatest resource on Earth, for the discovery of new bioactive compounds. Early National Cancer 
Institute (NCI) programs in the USA demonstrated that marine invertebrates were a superb source of 
potential lead molecules. The decisive boost to this new age of bioprospecting was provided by the 
NCI when it was found that bioassays with marine organism extracts were far more likely to yield 
anticancer drugs than terrestrial sources [2]. In this way, it is not surprising that over the past 40 years 
major advances in the discovery of marine drugs have been recorded in clinical trials for cancer [3]. 
Apart from anticancer activity, these compounds have proven to be an abundant source of 
pharmacologically active agents for the production of therapeutic entities [4] against AIDS, 
inflammatory conditions and microbial diseases. 
Marine bioactive compounds display varied potential applications, namely as molecular tools, in 
cosmetics, as fine chemicals, as nutraceuticals and in agrochemical industries [5]. 
Although only a few marine-derived products are currently on the market (e.g., Prialt
® and 
Yondelis
®), several new compounds are now in the clinical pipeline and several more are in clinical 
development. The few approvals so far for the commercialization of drugs from the sea have not been 
due to a lack of discovery of novel marine bioactive compounds, but because of the complexity of 
issues raised upon the development of these products [4]. Faulkner [6–20], Blunt et al. [21–29], and 
Mayer [30–38] have provided extensive reviews on the total number of marine natural products 
(MNPs) discovered over the last 25 years, the most promising ones being produced by marine 
invertebrates. Sponges (phylum Porifera) have long been recognized as the most interesting group of 
marine invertebrates for the discovery of new drugs [5,39,40]. However, with growing bioprospecting 
efforts and the screening of previously unexplored marine habitats, the biotechnological potential of 
other groups of marine invertebrates has also started to attract the attention of researchers. The ability 
of cnidarians (such as jellyfish, sea anemones and corals) to produce powerful toxins and venoms [41] 
has been well documented. However, further research has demonstrated that MNPs produced by 
cnidarians are more than toxins and venoms. The phylum Cnidaria is a large, diverse and ecologically 
important group of marine invertebrates that includes over 11,000 extant species [42]. Over 3000 MNPs 
have been described from this phylum alone, mostly in the last decade. 
In this work, we present an overview of the most promising marine bioactive compounds isolated 
from cnidarians in the first decade of the 21st century, which may have applications in the therapy of 
human diseases. The present study also discusses future perspectives for the bioprospecting of new 
MNPs produced by this speciose group of marine invertebrates. 
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2. Methodology 
The most relevant peer reviewed literature published during the first decade of the 21st century 
covering MNPs was surveyed for the present work [18–37]. During this period alone, over 
2000 molecules from cnidarians were described. In order to focus our study and address only those 
compounds displaying a high potential for industrial applications, we have decided to use as guidelines 
the values of IC50 (half maximal inhibitory concentration). IC50 is a quantitative measure which 
indicates how much of a particular substance (inhibitor) is needed to inhibit a given biological process 
or component of a process by half. It is important to highlight that the NCI has renamed the IC50 to 
GI50 [43] in order to emphasize the correction for cell count at time zero in cancer cells; in this way, 
some results on this quantitative measure are now also presented under these directives. Additionally, 
the ED50 (the median dose that produces the desired effect of a drug in half the test population) was 
also used to identify promising marine bioactive compounds produced by cnidarians. Only the 
compounds displaying an IC50 ≤ 10.0 µg/mL or µM (except where stated otherwise) and ED50 ≤ 4.0 µg/mL 
were considered for the present study, as these values are commonly used in the surveyed literature to 
ascertain relevant bioactivity (e.g., [44,45]). In the few cases were neither IC50 nor ED50 values were 
described for a MNP in a manuscript, that compound was selected to be part of the present survey only 
if either the authors of that manuscript, or those citing that manuscript, clearly stated that the results 
recorded were highly promising for industrial applications. All species producing the compounds 
selected for the present work were grouped into classes and orders of phylum Cnidaria (Table 1) 
(according to the classification proposed in the World Register of Marine Species (WoRMS)) [46].  
Table 1. Classes and orders in the phylum Cnidaria followed in this paper. 
Phylum Class  Order 
Cnidaria 
(≈11,287 species) 
Anthozoa (≈7500 species) 
Actiniaria 
Antipatharia 
Ceriantharia 
Corallimorpharia 
Scleractinia 
Zoanthidea 
Alcyonacea 
Gorgonacea 
Helioporacea 
Pennatulacea 
Cubozoa (≈36 species)  Carybdeida  Chirodropida 
Hydrozoa (≈3500 species) 
Anthoathecata 
Leptothecata 
Siphonophorae 
Actinulida 
Limnomedusae 
Narcomedusae 
Trachymedusae 
Polypodiozoa (1 species) 
Scyphozoa (≈200 species) 
Coronatae 
Rhizostomeae 
Semaeostomeae 
Staurozoa (≈50 species)  Stauromedusae 
This approach allowed us to identify which taxonomic groups of cnidarians screened so far display 
the highest potential to yield new drugs or pharmacological products derived from marine bioactive 
compounds. Nonetheless, it is important to highlight that cnidarian species identification is a 
challenging task and it is possible that some of the species (or even genera) referred to in the scientific 
literature may not be correct [47]. In this way, it is of paramount importance that in future works the Mar. Drugs 2011, 9 
 
1863
authors addressing marine bioactive compounds produced by cnidarians provide a detailed description 
on how target species have been identified. 
3. Class Anthozoa 
Class Anthozoa currently includes 10 orders and over 7500 valid species (about 2/3 of all known 
cnidarian species) (Table 1). Within the Anthozoa, the order Alcyonacea (soft corals) and Gorgonacea 
(sea fans) are the ones which have contributed with the highest number of promising bioactive marine 
compounds, although other orders, such as Actiniaria (sea anemones) and Scleractinia (hard corals), 
have also yielded relevant compounds [48–51]. 
3.1. Order Alcyonacea (Soft Corals) 
Soft corals are generally brightly colored and rich in nutritionally important substances. However, 
the incidence of predation in the majority of these organisms is low due to the toxic compounds they 
produce to deter predators [52]. Several biosynthetic studies have been carried out on the metabolites 
of soft corals [53] and some of those compounds have already shown to have great potential for the 
development of new pharmaceuticals and antifoulants. Table 2 summarizes the most promising 
compounds from order Alcyonacea (class Anthozoa) described in the present review. 
Table 2. Most promising compounds studied in the last decade from cnidarian species in 
order Alcyonacea (soft corals), class Anthozoa. 
Family and Species  Drug Class  Compound  Chemistry  Country  Ref.  
Alcyoniidae 
Klyxum simplex  Anti-inflammatory Simplexin E  Diterpenoid  TAIW  [54] 
Klyxum simplex  Antitumor  Klysimplexin B and H  Diterpenoid  TAIW  [55] 
Lobophytum sp. Antitumor  Lobophytene  Diterpenoid  VN  [56] 
Lobophytum sp.  Anti-HIV  Lobohedleolide  Diterpenoid  PHL  [57] 
Lobophytum sp.  Anti-HIV  (7Z)-lobohedleolide, Diterpenoid  PHL  [57] 
Lobophytum sp.  Anti-HIV  17-dimethylamino lobohedleolide  Diterpenoid  PHL  [57] 
Lobophytum crassum  Anti-inflammatory Crassumolides A and C  Terpenoid  TAIW  [58] 
Lobophytum cristagalli Antitumor  Cembranolide  diterpene  Diterpenoid  RSC  [59] 
Lobophytum durum Anti-inflammatory Durumolides  A–C  Terpenoid  TAIW  [60] 
Lobophytum durum  Anti-inflammatory Durumhemiketalolide A–C  Cembranoid  TAIW  [61] 
Sarcophyton crassocaule  Antitumor Crassocolides  H–M  Cembranoid  TAIW  [62] 
Sinularia sp.  Antiulcer  Sinulide  Spermine    [63] 
Sinularia sp.  Antimicrobial Lipids Polyketide  RUS  [64] 
Sinularia flexibilis  Antitumor Flexilarin  D  Cembranoid  TAIW  [65] 
Sinularia flexibilis  Antifoulant 11-episinulariolide  Diterpenoid  AUS  [66] 
Sinularia gibberosa  Anti-inflammatory Gibberoketosterol Steroid  TAIW  [67] 
Sinularia querciformis  Anti-inflammatory Querciformolide C  Terpenoid  TAIW  [68] 
Clavulariidae 
Clavularia sp. Nervous  system  Stolonidiol  Diterpenoid  JPN  [69] 
Clavularia koellikeri  Antitumor Cembrane-type  diterpenoid  Diterpenoid  JPN  [70] 
Clavularia viridis  Antitumor Claviridic  acid  Prostanoid  TAIW  [71] 
Clavularia viridis  Antitumor Clavulones  Prostanoid  TAIW  [71] Mar. Drugs 2011, 9 
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Table 2. Cont. 
Clavularia viridis  Antitumor Claviridenone  Prostanoid  TAIW  [45] 
Clavularia viridis  Antitumor Halogenated  prostanoids  Prostanoid  JPN  [72] 
Clavularia viridis  Antitumor Bromovulone  III  Prostanoid  TAIW  [73,74] 
Clavularia viridis  Antitumor Yonarasterols Steroid  JPN  [75] 
Clavularia viridis  Antitumor Stoloniferone  E Steroid  TAIW  [45] 
Telesto riisei  Antitumor Punaglandins  Prostaglandin  USA  [76] 
Nephtheidae 
Dendronephthya sp.  Antifoulant Isogosterones  A–D  Steroid  JPN  [77] 
Dendronephthya rubeola  Antitumour Capnell-9(12)-ene-8β,10α-diol Sesquiterpenoid  DE [78,79,80]
Nephthea chabroli  Antitumor Chabranol  Terpenoid  TAIW  [81] 
Nephthea erecta  Anti-inflammatory Ergostanoids 1 and 3  Ergostanoid  TAIW  [82] 
Xeniidae 
Asterospicularia laurae  Antitumor Asterolaurin  A  Diterpenoid  TAIW  [83] 
Cespitularia hypotentaculata  Antitumor Cespitularin  C  Diterpenoid  TAIW  [84] 
Xenia novaebritanniae Antibacterial  Xeniolide  I  Diterpenoid  ISR  [85] 
Xenia plicata Antitumor  Blumiolide  C  Diterpenoid  TAIW  [44] 
AUS: Australia; DE: Germany; ISR: Israel; JPN: Japan; PHL: Philippines; RSC: Republic of Seychelles; RUS: Russia; 
TAIW: Taiwan; VN: Vietnam.  
Soft corals are rich sources of secondary metabolites such as diterpenes, sesquiterpenes, 
furanoditerpenes, terpenoids, capnellenes and steroids (e.g., Lobophytum, Sinularia (Figure 1A), 
Sarcophyton [86] (Figure 1C), Capnella [87], Dendronephthya [78]), that have shown to   
display HIV-inhibitory [57], cytotoxic [88,89], anti-inflammatory [90,91], anticancer [92,93] and 
antimicrobial activity [94], as well as cardiac and vascular responses [95]. Soft corals of the family 
Nephtheidae are known for their content of sesquiterpenes and particularly capnellenes [28]. Some 
sesquiterpenes isolated from Capnella imbricate [87,96–98] showed anti-inflammatory activity and a 
dihydroxycapnellene (capnell-9(12)-ene-8β,10α-diol) from Dendronephthya rubeola demonstrated a 
good antiproliferative activity against murine fibroblasts cell line (L-929, GI50 6.8 µM/L) and a good 
cytotoxicity against cancer cell lines implicated in human leukemia (K-562, IC50 0.7 µM) and   
human cervix carcinoma (HeLa, IC50 7.6 µM) [78]. Capnell-9(12)-ene-8β,10α-diol strongly inhibits 
the interaction of the oncogenic transcription factor Myc with its partner protein Max [79,80], making 
it a therapeutically interesting compound in oncology [78]. Nephthea chabroli also produces a   
nor-sisquiterpene compound, chabranol, which displays moderate cytotoxicity against P-388 (mouse 
lymphocytic leukemia cells) with an ED50 1.81 µg/mL [81]. Nephthea erecta produces two proteins in 
mediated inflammatory responses, the oxygenated ergostanoids 1 and 3. These compounds at a 
concentration of 10 µM significantly reduced the levels of the iNOS (inducible nitric oxide synthase) 
(45.8 ± 9.9 and 33.6 ± 20.6%, respectively) and COX-2 (cyclooxygenase-2) protein (68.1 ± 2.3 and 
10.3 ± 6.2%, respectively), when compared with the control cells stimulated with lipopolysaccharides 
(LPS) [82].  
Species in the genus Xenia (family Xeniidae) (Figure 1B) are a rich source of diterpenoids. 
Xeniolides I, isolated from Xenia novaebrittanniae demonstrated antibacterial activity at a 
concentration of 1.25 mg/mL in Escherichia coli ATCC and Bacillus subtilis [85]. Blumiolide C, a 
diterpenoid from the Xenia blumi (presently accepted as Xenia plicata), exhibited potent cytotoxicity Mar. Drugs 2011, 9 
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against mouse lymphocytic leukemia (P-388, ED50 0.2 µg/mL) and human colon adenocarcinoma 
(HT-29, ED50 0.5 µg/mL) cells [44]. 
Figure 1. Some cnidarians addressed in this review (all images by Ricardo Calado).   
(A) Sinularia sp.; (B) Xenia sp.; (C) Sarcophyton sp.; (D) Briareum sp.  
 
Polyoxygenated cembranoids, crassocolides H–M from Sarcophyton crassocaule, demonstrated 
cytotoxicity against cancer cell lines of human medulloblastoma (Daoy cells) where crassocolides I 
and M were found to be more active (IC50 0.8 and 1.1 μg/mL, respectively). Crassocolide H was also 
found to inhibit the growth of human oral epidermoid carcinoma (KB) cells (IC50 5.3 μg/mL) and 
crassocolide L active against human cervical epitheloid carcinoma (HeLa) cells (IC50 8.0 μg/mL) [62]. 
Another example of a potential new therapeutic anticancer agent is a cembranolide diterpene from 
Lobophytum cristagalli, which has shown a potent inhibitory activity (IC50 0.15 μM) [59] over farnesyl 
protein transferase (FPT, an important protein in signal transduction and regulation of cell 
differentiation and proliferation [99]). This type of FPT inhibition enhanced interest in this group  
of metabolites [86]. Other species of this genus also showed cembranolide diterpenes (lobophytene) 
with significant cytotoxic activity against human lung adenocarcinoma (A549) and human colon 
adenocarcinoma (HT-29) cell lines [56]. Lobophytum durum and Lobophytum crassum produce 
durumolides A–C [60], durumhemiketalolide A–C [61] and crassumolides A and C [58], with   
anti-inflammatory effects. They have been shown to inhibit up-regulation of the pro-inflammatory 
iNOS and COX-2 proteins in LPS-stimulated murine macrophage cells at IC50 < 10 µM [58,60]. The 
diterpenoids, lobohedleolide, (7Z)-lobohedleolide, and 17-dimethylaminolobohedleolide, were isolated 
from the aqueous extract of Lobophytum species and exhibited moderate HIV-inhibitory activity   
(IC50 approximately 7–10 μg/mL) in a cell-based in vitro anti-HIV assay [57]. 
Klyxum simplex produces diterpene compounds, such as simplexin E, which at a concentration of 
10 μM was found to considerably reduce the levels of iNOS and COX-2 proteins to 4.8 ± 1.8% and 
37.7 ± 4.7%, respectively. These results have shown that this compound significantly inhibits the 
accumulation of the pro-inflammatory iNOS and COX-2 proteins in LPS-stimulated RAW264.7 
macrophage cells [54]. This species also produces two diterpene compounds, klysimplexins B and H, 
exhibiting moderate cytotoxicity towards human carcinoma cell lines. Klysimplexin B exhibits 
B 
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cytotoxicity toward human hepatocellular carcinoma (Hep G2 and Hep 3B), human breast carcinoma 
(MDA-MB-231 and MCF-7), human lung carcinoma (A549) and human gingival carcinoma (Ca9-22) 
cell lines with IC50’s of 3.0, 3.6, 6.9, 3.0, 2.0, and 1.8 μg/mL, respectively. Metabolite klysimplexin H 
demonstrated cytotoxicity (IC50’s 5.6, 6.9, 4.4, 5.6, 2.8 and 6.1 μg/mL) toward human hepatocellular 
carcinoma (Hep G2 and Hep 3B), human breast carcinoma (MDA-MB-231 and MCF-7), human lung 
carcinoma (A549) and human gingival carcinoma (Ca9-22) cell lines, respectively [55]. 
In Sinularia sp. (Figure 1A), a tetraprenylated spermine derivative has been isolated—sinulamide—
which revealed an H,K-ATPase inhibitory activity. H,K-ATPase is a gastric proton pump of stomach 
and is the enzyme primarily responsible for the acidification of the stomach contents. Its inhibition is a 
very common clinical intervention used in diseases including dyspepsia, peptic ulcer, and gastroesophageal 
reflux (GORD/GERD). Sinulide is a potential antiulcer drug, as it inhibits production of gastric acid by 
H,K-ATPase (IC50 5.5 μM) [63]. Although it has been synthesized [100], no clinical trials seem to 
have been reported. The steroid gibberoketosterol [67], isolated from Sinularia gibberosa, and the 
diterpenoid querciformolide C [68] from Sinularia querciformis, showed significant inhibition of the 
up-regulation of the pro-inflammatory iNOS and COX-2 proteins in LPS-stimulated murine 
macrophages at concentration <10 μM [67,68]. Paralemnalia thyrsoides showed significant inhibition 
of pro-inflammatory iNOS protein expression (70% at IC50 10 µM) [101]. Sinularia species produce 
significant molecules: lipids from Sinularia grandilobata and another unspecified species of   
Sinularia possesses antibacterial and antifungal activity [64]. The diterpene 11-episinulariolide from 
Sinularia flexibilis is an interesting antifoulant exhibiting strong algacidal properties [66]. This species 
also produces cembrenoids, named flexilarins, which evidence cytotoxic activity in cancer cell lines. 
Flexilarin D exhibited potent cytotoxicity in human hepatocarcinoma (Hep2) cells with IC50 0.07 μg/mL, 
and moderate cytotoxic activity against human cervical epitheloid carcinoma (HeLa, IC50 0.41 μg/mL), 
human medulloblastoma (Daoy, 1.24 μg/mL) and human breast carcinoma (MCF-7, 1.24 μg/mL) 
cell lines [65]. 
Antifouling agents from natural sources are of increasing interest since the International Maritime 
Organization (IMO) banned the use of certain antifouling agents, such as tri-n-butyltin (TBT), due to 
the ecological impacts of these biocides in the marine environment. Several studies have demonstrated 
that soft corals can yield large quantities of promising antifouling metabolites [102,103]. In fact,   
17.95% of potential antifouling natural compounds are from cnidarians (e.g., soft coral) [104]. One of 
the most promising natural antifouling agent identified so far is an isogosterone isolated from an 
unspecified Dendronephthya [77]. 
The genus Clavularia contains secondary metabolites with unique structures and remarkable biological 
activities. Some of the species in this genus produce prostanoids (icosanoids) [45,72,73,105,106], 
steroids [75] and diterpenoids [70,107]. The bioactive marine diterpene, stolonidiol, isolated from an 
unidentified Clavularia, showed potent choline acetyltransferase (ChAT) inducible activity in primary 
cultured basal forebrain cells and clonal septal SN49 cells, suggesting that it may act as a potent 
neurotrophic factor-like agent on the cholinergic nervous system [69]. Cholinergic neurons in the basal 
forebrain innervate the cortex and hippocampus, and their function may be closely related to cognitive 
function and memory. The degeneration of neuronal cells in this brain region is considered to be 
responsible for several types of dementia including Alzheimer’s disease. One of the neurotransmitters, 
acetylcholine, is synthesized from acetyl coenzyme A and choline by the action of ChAT. Therefore, Mar. Drugs 2011, 9 
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induction of ChAT activity in cholinergic neurons may improve the cognitive function in diseases 
exhibiting cholinergic deficits [108–110]. 
Prostanoids (claviridic acid) isolated from Clavularia viridis exhibited potent inhibitory effects   
on phytohemagglutinin-induced proliferation of peripheral blood mononuclear cells (PBMC, 
5 μg/mL), as well as significant cytotoxic activity against human gastric cancer cells (AGS, IC50  
1.73–7.78  μg/mL) [71]. Claviridenone extracts also showed potent cytotoxicity against mouse 
lymphocytic leukemia (P-388) and human colon adenocarcinoma (HT-29), and exceptionally potent 
cytotoxicty against human lung adenocarcinoma (A549) cells, with ED50 between 0.52 pg/mL and 
1.22 μg/mL [45]. Halogenated prostanoids also showed cytotoxic activity against human T lymphocyte 
leukemia cells (MOLT-4, IC50 0.52 µg/mL), human colorectal adenocarcinoma (DLD-1, IC50 0.6 µg/mL) 
and human diploid lung fibroblast (IMR-90, IC50 4.5 µg/mL) cells [72]. The cyclopentenone 
prostanoid, bromovulone III-a promising marine natural compound for treatment of prostate, colon and 
hepatocellular carcinoma-showed anti-tumor activity against human prostate (PC-3) and human colon 
(HT29) cancer cells at an IC50 of 0.5 µM [73], and induced apoptotic signaling in a sequential manner 
in Hep3B cells [74]. In the case of prostate cancer cells, this compound displayed an anti-tumor 
activity 30 to 100 times more effective than cyclopentenone prostaglandins (known to suppress tumor 
cell growth and to induce apoptosis in prostate cancer cells), by causing a rapid redistribution and 
clustering of Fas (member of the tumor necrosis factor (TNF) receptor superfamily). Apoptotic 
stimulation of Fas by specific ligand or antibodies causes the formation of a membrane-associated 
complex comprising Fas clustering) in PC-3 cells [111]. C. viridis also produces steroids that show 
cytotoxic activity against human colorectal adenocarcinoma (DLD-1, 0.02 < IC50 < 50 µg/mL) and 
also against human T lymphocyte leukemia cells (MOLT-4, 0.01 < IC50 < 10 µg/mL), in the case of 
yonarasterols [75]. Stoloniferone additionally displayed potent cytotoxicity against mouse lymphocytic 
leukemia (P-388), human colon adenocarcinoma (HT-29) and human lung adenocarcinoma (A549) 
cells [45]. This species produces several compounds with anti-tumor activity in different types of 
human tumors, although more in vitro studies are needed to determine which compound are potential 
anticancer agents. Clavularia koellikeri produces diterpenoids as secondary metabolites, which display 
cytotoxic activity against human colorectal adenocarcinoma (DLD-1, IC50 4.2 µg/mL) and strong 
growth inhibition against human T lymphocyte leukemia cells (MOLT-4, IC50 0.9 µg/mL) [70]. 
In the genus Cespitularia, several interesting diterpenes of cembrane and neodolabellane skeletons 
have been identified. In Cespitularia hypotentaculata (family Xeniidae) a significant production of 
diterpenoids was detected. Cespitularin C exhibited potent cytotoxicity against mouse lymphocytic 
leukemia (P-388, ED50 0.01 µg/mL) and human lung adenocarcinoma (A549, ED50 0.12 µg/mL) cells, 
while cespitularin E exhibited potent cytotoxicity against human lung adenocarcinoma (A549, ED50 
0.034 µg/mL) cell cultures [84]. A less active diterpene, Asterolaurin A, from Asterospicularia laurae (a 
species from the same family) exhibited cytotoxicity against human hepatocellular carcinoma (HepG2) 
cells with an IC50 8.9 µM [83]. 
Telesto riisei produces punaglandins, highly functional cyclopentadienone and cyclopentenone 
prostaglandins. Cyclopentenone prostaglandins have unique antineoplastic activity and are potent 
growth inhibitors in a variety of cultured cells. These punaglandins have been shown to inhibit   
P53 accumulation (a tumor suppressor protein) and ubiquitin isopeptidase activity (IC50 between   
0.04 and 0.37 µM) (enzyme involved in protein degradation system) in vitro and in vivo [76]. Since Mar. Drugs 2011, 9 
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these proteasome inhibitors exhibit higher antiproliferative effects than other prostaglandins [112], 
they may represent a new class of potent cancer therapeutics. 
3.2. Order Gorgonacea (Sea Fans) 
Gorgonians are a well-known source of compounds exhibiting significant biological activity [113]. 
Table 3 summarizes the most promising compounds from order Gorgonacea (class Anthozoa) 
described in the present review. Studies on Isis hippuris have resulted in the isolation of a series of 
novel metabolites such as sesquiterpenes [114], steroids [115], A-nor-hippuristanol [116] and 
isishippuric acid B [116]. These compounds exhibit potent cytotoxicity against cancer cell lines of 
human hepatocellular carcinoma (HepG2 and Hep3B, IC50 0.08–4.64 µg/mL and 0.10–1.46 µg/mL, 
respectively) [116,117], human breast carcinoma (MCF-7, IC50 0.20–4.54 µg/mL and MDA-MB-231, 
IC50 0.13–2.64 µg/mL) [117], mouse lymphocytic leukemia (P-388), human lung adenocarcinoma 
(A549), and human colon adenocarcinoma (HT-29) with ED50 values less than 0.1 µg/mL [115,116] 
and IC50 of 0.1 µg/mL [114]. 
Table 3. Most promising compounds studied in the last decade from cnidarian species in 
order Gorgonacea (sea fans), class Anthozoa. 
Family and Species  Drug Class  Compound  Chemistry  Country  Ref.  
Briareidae 
Briareum excavate  Anti-inflammatory Briaexcavatin E  Diterpenoid  TAIW  [118] 
Briareum excavate  Antitumor  Briaexcavatolides L and P Diterpenoid  TAIW  [119] 
Briareum asbestinum  Antimalarial  Briarellin D, K and L Diterpenoid  PAN,  USA  [120] 
Ellisellidae 
Junceella fragilis  Anti-inflammatory Frajunolides B and C  Terpenoid  TAIW  [121] 
Junceella juncea  Antifoulant Juncin  ZII  Diterpenoid  TAIW  [122] 
Gorgoniidae 
Leptogorgia setácea  Antifoulant Homarine Pyridine  GEO  [123] 
Leptogorgia virgulata  Antifoulant Homarine Pyridine  GEO  [123] 
Leptogorgia virgulata  Antifoulant Pukalide  Diterpenoid  USA  [124] 
Leptogorgia virgulata  Antifoulant Epoxypukalide  Diterpenoid  USA  [124] 
Pseudopterogorgia sp.  Antitumor  Secosterols  Sterol  USA  [125] 
Pseudopterogorgia sp.  Anti-inflammatory Secosterols  Sterol  USA  [125] 
Pseudopterogorgia acerosa  Antitumor Bis(pseudopterane)  amine Dialkylamine  BHS  [126] 
Pseudopterogorgia bipinnata  Antituberculosis Bipinnapterolide  B  Terpenoid  USA  [127] 
Pseudopterogorgia bipinnata  Antimalarial  Caucanolide A and D  Diterpenoid  COL, PAN, USA [128] 
Pseudopterogorgia elisabethae Antimicrobial Pseudopterosin  X Diterpenoid  USA  [129] 
Pseudopterogorgia elisabethae Antituberculosis Ileabethoxazole Diterpenoid  USA  [130] 
Pseudopterogorgia elisabethae Antituberculosis Homopseudopteroxazole Diterpenoid  USA  [131] 
Pseudopterogorgia elisabethae Antituberculosis  Caribenols A and B  Terpenoid  USA  [132] 
Pseudopterogorgia elisabethae Antituberculosis Elisapterosin  B  Diterpenoid  USA  [133] 
Pseudopterogorgia elisabethae Antimalarial Aberrarone  Diterpenoid  COL  [134] 
Pseudopterogorgia kallos  Antimalarial Bielschowskysin  Diterpenoid  PAN,  USA  [135] 
Pseudopterogorgia kallos  Antitumor Bielschowskysin  Diterpenoid  PAN,  USA  [135] 
Pseudopterogorgia rígida  Antimicrobial Curcuphenol Terpenoid USA  [136] Mar. Drugs 2011, 9 
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Table 3. Cont. 
Isididae 
Isis hippuris  Antitumor Suberosenol  B  Terpenoid  TAIW  [114] 
Isis hippuris  Antitumor Polyoxygenated  steroids Steroid  IND  [115,117]
Isis hippuris  Antitumor A  –nor-hippuristanol Steroid  TAIW  [116] 
Isis hippuris  Antitumor Isishippuric  acid  B Steroid  TAIW  [116] 
Plexauridae 
Eunicea sp.  Antimalarial Sesquiterpenoids  Sesquiterpenoid  COL, PAN, USA [137] 
Eunicea fusca  Anti-inflammatory Fuscisides Diterpenoid  USA  [138] 
Euplexaura flava  Anti-inflammatory Butenolide Lipid  JPN  [139] 
ND: Not Determined; BHS: Bahamas; COL: Colombia; GEO: Georgia; IND: Indonesia; PAN: Panama; TAIW: Taiwan; 
USA: United States of America. 
Species from the genus Pseudopterogorgia are a rich source of unusual biologically active diterpenoids, 
sesquiterpenes, and polyhydroxylated steroids, which exhibit diverse structures [127,140,141]. A 
sample of the organic extract of Pseudopterogorgia bipinnata was included in an initial screening 
carried out as part of an effort in the discovery of new antimalarial agents. This extract was found to be 
active in inhibiting the growth of Plasmodium falciparum (a protozoan parasite responsible for the 
most severe forms of malaria). Caucanolide A and D demonstrated significant in vitro antiplasmodial 
activity against chloroquine-resistant P. falciparum W2 (IC50 17 µg/mL and IC50 15 µg/mL, 
respectively) [128]. Three secosterols isolated from an unidentified gorgonian from genus 
Pseudopterogorgia inhibited human protein kinase C (PKC) α, βI, βII, γ, δ, ε, η, and ζ, with IC50 
values in the range 12–50 μM [125]. PKC is a key player in cellular signal transduction and has been 
implicated in cancer, cardiovascular and renal disorders, immunosuppression, and autoimmune diseases 
such as rheumatoid arthritis [99]. Semisynthetic derivatives also showed a similar activity [125]. 
Promising antimicrobial substances were also reported from Pseudopterogorgia rigida (e.g., 
curcuphenol) [136] and from Pseudopterogorgia elisabethae (e.g., pseudopterosin X and Y) [129]. 
Ileabethoxazole, homopseudopteroxazole, caribenols A and B and elisapterosin B from P. elisabethae 
and bipinnapterolide B from P. bipinnata inhibit Mycobacterium tuberculosis H37Rv at a concentration 
of 12.5 µg/mL [131,133] (for elisapterosin B and homopseudopteroxazole) and at a concentration 
range of 128–64 µg/mL [130,132,142] (for others compounds). In fact, the inhibition of M. tuberculosis 
H37Rv is within the ranges recorded for rifampin [130]. P. elisabethae and P. bipinnata also produce 
antituberculosis compounds. Bielschowskysin, a naturally occurring diterpene isolated from 
Pseudopterogorgia  kallos [135]  and aberrarone isolated from P. elisabethae [134] exhibited 
antiplasmodial activity (IC50 10 μg/mL) when tested against P. falciparum. The first compound was 
also found to display strong and specific in vitro cytotoxicity against the EKVX non-small cell lung 
cancer (GI50 < 0.01 μM) and CAKI-1 renal cancer (GI50 0.51 μM) [135]. Bis(pseudopterane) amine 
from Pseudopterogorgia acerosa was found to exhibit selective activity against HCT116 (IC50 4 μM) 
cell lines [126]. 
Fuscosides, originally isolated from Eunicea fusca [138], selectively and irreversibly inhibited 
leukotriene synthesis. Leukotrienes are molecules of the immune system that contribute to inflammation 
in asthma and allergic rhinitis and its production is usually related to histamine release [143]. 
Pharmacological studies indicated that fuscoside B inhibits the conversion of arachidonic acid (AA) to Mar. Drugs 2011, 9 
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leukotriene B4 and C4 (LTB4 and LTC4) [138,144] by inhibiting the 5-Lipoxygenase (5-LO), in the 
case of LTB4 with an IC50 of 18 μM [144]. These selective inhibitors of lipoxygenase isoforms can  
be useful as pharmacological agents, as nutraceuticals or as molecular tools [99]. Sesquiterpenoids 
metabolites isolated from Eunicea sp. display antiplasmodial activity against the malaria parasite   
P. falciparum W2 (chloroquine-resistant) strain, with IC50 values ranging from 10 to 18 µg/mL [137]. 
The gorgonian Junceella fragilis produces secondary metabolites, frajunolides B and C, with   
anti-inflammatory effects towards superoxide anion generation and elastase release by human 
neutrophils, with an IC50 > 10 µg/mL [121]. When properly stimulated, activated neutrophils secrete a 
series of cytotoxins, such as the superoxide anion (O2
•−), a precursor of other reactive oxygen species 
(ROS), granule proteases, and bioactive lipids [145,146]. The production of the superoxide anion is 
linked to the killing of invading microorganisms, but it can also directly or indirectly damage 
surrounding tissues. On the other hand, neutrophil elastase is a major secreted product of stimulated 
neutrophils and a major contributor to the destruction of tissue in chronic inflammatory disease [147]. 
The anti-inflammatory butenolide lipide [148] from the gorgonian Euplexaura flava [139] can be currently 
synthesized, opening the possibility of advancing into a new level of anti-inflammatory pharmaceuticals. 
Some of the most interesting compounds identified so far in the on-going search for new   
anti-fouling agents have been recorded in the order Gorgonacea. Good examples of such compounds 
are juncin ZII from Junceella juncea [122], homarine from Leptogorgia virgulata and  
Leptogorgia setacea [123], pukalide and epoxypukalide recorded so far only from L. virgulata [124]. 
Species of genus Briareum (family Briareidae) (Figure 1D) (which commonly exhibit an incrusting 
appearance rather than the fan-like shape of many gorgonians) are widely abundant in Indo-Pacific and 
Caribean coral reefs. These organisms have been recognized as a valuable source of bioactive 
compounds with novel structural features. Briarane-related natural products are a good example of 
such promising compounds due to their structural complexity and biological activity [149,150]. 
Briaexcavatin E, from Briareum excavata (Nutting 1911), also occasionally referred to as 
Briarium excavatum, inhibited human neutrophil elastase (HNE) release with an IC50 between 5 and 
10 µM [118]. Briaexcavatolides L and P, diterpenoids from the same species exhibited significant 
cytotoxicity against mouse lymphocytic leukemia (P-388) tumor cells with ED50 of 0.5 [119] and 
0.9 μg/mL [151], respectively. Diterpenoids produced from Briareum polyanthes (presently accepted 
as  Briareum asbestinum),  namely Briarellin D, K and L, exhibited antimalarial activity against 
P. falciparum with an IC50 between 9 and 15 µg/mL [120]. 
3.3. Other Orders 
Sea anemones (order Actiniaria) are a rich source of biologically-active proteins and polypeptides. 
Several cytolytic toxins, neuropeptides and protease inhibitors have been identified from them [48]. In 
addition to several equinatoxins, potent cytolytic proteins and an inhibitor of papain-like cysteine 
proteinases (equistatin), were isolated from the sea anemone Actinia equina [152]. Equistatin has been 
shown to be a very potent inhibitor of papain and a specific inhibitor of the aspartic proteinase 
cathepsin D [153]. While papain-like cysteine proteases have been implicated in various diseases of 
the central nervous system, such as brain tumors, Alzheimer’s disease, stroke, cerebral lesions, Mar. Drugs 2011, 9 
 
1871
neurological autoimmune diseases and certain forms of epilepsy [154], aspartic proteinase cathepsin D 
is involved in the pathogenesis of breast cancer [155] and possibly Alzheimer’s disease [156].  
Cycloaplysinopsin C, a bis(indole) alkaloid isolated from Tubastrea sp. (order Scleractinia), was 
found to inhibit growth of two strains of P. falciparum, one chloroquine-sensitive (F32/Tanzania) and 
other chloroquine-resistant (FcB1/Colombia) with IC50 1.48 and 1.2 μg/mL, respectively [51]. 
Cladocorans A and B, isolated from Cladocora caespitosa (order Scleractinia) [49], are marine 
sesterterpenoids which possess a γ-hydroxybutenolide moiety, which is thought to be responsible for 
the biological activity of these compounds. The potent anti-inflammatory activity of these natural 
metabolites was attributed to the inhibition of secretory phospholipase A2 (sPLA2, IC50 0.8–1.9 μM). 
Given the general role of inflammation in diseases that include bronchial asthma and rheumatoid 
arthritis, identifying and developing potent inhibitors of sPLA2 continues to be of great importance for 
the pharmaceutical industry, with this type of metabolite being of paramount importance for future 
research [50]. 
4. Class Hydrozoa 
Class Hydrozoa includes seven orders and nearly 3500 valid species (Table 1), some of which are 
solitary, some of which are colonial. Among the most emblematic species are probably hydroids and 
the Portuguese man-o-war (Physalia physalis). Despite the large number of species in class Hydrozoa, 
only a few of them have yielded interesting MNPs in the last decade. 
Immune escape plays an important role in cancer progression and, although not completely 
understood, it has been proposed that indoleamine 2,3-dioxygenase (IDO) plays a central role in 
evasion of T-cell-mediated immune rejection [157]. IDO catalyzes the oxidative cleavage of the   
2,3 bond of tryptophan, which is the first and rate-limiting step in the kynurenine pathway of 
tryptophan catabolism in mammalian cells [158]. The polyketides annulins A, B, and C, purified   
from the marine hydroid Garveia annulata (order Anthoathecata), potently inhibited IDO in vitro   
(Ki 0.12–0.69 μM) [159]. These annulins are more powerful than most tryptophan analogues known to 
be IDO inhibitors. These compounds are active at concentrations higher than ~10 μM and therefore 
more effective than 1-methyltryptophan (Ki 6.6 μM), one of the most potent IDO inhibitors currently 
available [160]. Solandelactones C, D, and G are cyclopropyl oxylipins isolated from the hydroid 
Solanderia secunda (order Anthoathecata) and exhibit moderate inhibitory activity against farnesyl 
protein transferase (FPT, 69, 89, and 61% inhibition, respectively) at a concentration of 100 μg/mL [161]. 
Note that FPT is associated with cell differentiation and proliferation and its inhibition may be a target 
for novel anticancer agents (as already referred above for the soft coral L. cristagalli). 
5. Class Scyphozoa 
Approximately 200 species are currently classified in three orders in class Scyphozoa (Table 1). 
However, in the last decade, only a single MNP purified from the mesoglea of the jellyfish 
Aurelia aurita (order Semaeostomeae) was considered to be promising enough to be included in the 
present work. This compound is a novel endogenous antibacterial peptide, aurelin, which exhibited 
activity against Gram-positive and Gram-negative bacteria. As an example, aurelin displayed an IC50 
of 7.7 µg/mL for Esherichia coli (Gram negative bacteria) [162]. Mar. Drugs 2011, 9 
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6. Other Classes 
The classes Staurozoa, Cubozoa and Polypodiozoa are the least speciose in the phylum Cnidaria 
(Table 1). This fact may explain the current lack of data on secondary metabolites produced by these 
organisms. It is possible that with growing bioprospecting new MNPs may be revealed once these 
cnidarian species are screened. Cubozoa (box jellies), for example, produce some of the most harmful 
cnidarian toxins for humans [163]. 
7. Exploring the Unexplored and Being Creative: Future Perspectives for the Bioprospecting  
of Cnidarians 
For several years, the bioprospecting of cnidarians was commonly limited to habitats that could be 
readily sampled by researchers, such as shallow coral reefs and the intertidal region. However, with 
improvements in SCUBA gear, researchers are now able to dive deeper and longer, allowing them to 
collect a wider range of cnidarian species for the screening of MNPs. The growing efforts to explore 
Earth’s last frontier, the deep sea, made it possible to start bioprospecting several unique marine 
ecosystems that had remained either previously unrecorded or inaccessible to researchers [164]. New 
cnidarian species (some of them belonging to new genera and probably even to new families)   
(e.g., [165,166]) are currently being sampled from the deep sea. These findings suggest that many new 
species are yet to be discovered along deep continental margins [167] and open good perspectives for 
the discovery of new MNPs with ongoing surveys of deep sea fauna. Cnidarians are known to colonize 
unique deep sea biotopes, namely chemosynthetic sites (such as hydrothermal vents, cold seeps and 
whale falls [168]), as well as seamounts [169]. Some of these organisms are endemic to these habitats 
and display remarkable adaptations to extreme environments (e.g., chemosynthetic sea anemones) [170]. 
These species are certainly interesting candidates for the discovery of new MNPs [171]. However, 
some of these remarkable biotopes, namely deep sea coral reefs, are already facing serious threats to 
their conservation [169] and thus, the bioprospecting of these and other endangered habitats must be 
carefully addressed [164,172]. 
Another interesting source of cnidarian species for bioprospecting is the marine aquarium industry. 
Over 200 species of hard and soft corals, along with several other anemone, zoanthid and corallimorph 
species, are harvested every year from coral reefs to supply the marine aquarium trade [173]. However, 
researchers using these organisms in the bioprospecting of new MNPs must be aware that it is not 
commonly possible to get reliable information on either the place of origin or the scientific name of 
most traded specimens. With the advent of high-throughput screening (HTS) [174], it will be possible 
to rapidly survey these organisms for interesting MNPs, although HTS of natural sources may present 
several challenges (see [175,176]). If necessary, additional biomass of target organisms producing 
interesting MNPs can be achieved using inexpensive techniques [177,178] and eliminate problems 
commonly faced by researchers screening marine organisms for MNPs–the loss of the source and 
reproducibility [176].  
The discovery of a new compound commonly requires only small amounts of biomass. However 
the production of these compounds at a scale large enough to fulfill commercial applications is still 
nearly impossible [179]. In theory, large-scale production of bioactive compounds can be achieved by Mar. Drugs 2011, 9 
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chemical synthesis or through extraction from marine animals, either harvested from the sea or 
maricultured. The existence of ecophysiological diversity (e.g., differences between individuals often 
due to differences in environmental interactions) can interfere with the production of MNPs and must 
be carefully addressed in future efforts for large-scale production of these compounds. The harvest of 
target animals from the wild for the production of chemical compounds is commonly an unsustainable 
solution, while mariculture has proven to be more technically challenging and expensive than 
previously assumed [180]. In other considerations, chemical synthesis is not yet developed to 
synthesize complex molecules at the kilogram scale and, in cases where this may already be 
technically possible, most of the compounds cannot be synthesized at a price affordable for 
commercial applications [179]. Potential solutions for such bottlenecks may be the use of diverted total 
synthesis [181] and/or metabolic engineering [182]. 
There is growing evidence that microbes associated with marine invertebrates may be the true 
producers of some of the bioactive compounds isolated from these animals [179]. Whether this is the case 
of bioactive compounds currently assumed to be produced by cnidarians remains unanswered [183,184]. 
If so, we face another constraint for the commercial use of these compounds, as the culture of 
symbiotic microorganisms is generally not possible using classic/standardized methodologies. 
8. Conclusions 
The intense pressure to find and develop more profitable molecules for all sorts of industries 
continues to fuel the bioprospecting of marine invertebrates. Although the phylum Cnidaria is not the 
most significantly bioprospected at present, this review shows that some cnidarian species are 
promising sources of marine bioactive compounds of medical, economic and scientific interest. Green 
fluorescent protein (GFP), GPF-like proteins, red fluorescent and orange fluorescent protein (OPF) are 
good examples of biotechnological metabolites currently employed as molecular biomarkers. They 
were first purified from a fluorescent hydrozoan medusa [185] and since then have been recorded in 
other cnidarian species [186–191]. 
In the present survey, only about 0.31% of extant cnidarian species are represented, with class 
Anthozoa displaying by far the highest number of promising MNPs (Figure 2). This result is probably 
due to the fact that this class is the most speciose in the phylum (Table 1). Additionally, many 
anthozoans occupy marine habitats which can be readily accessed for the collection of biomass   
(e.g., coral reefs and intertidal regions), which facilitates bioprospecting. Of all the compounds 
presented in this review, 84% were detected in cnidarians collected from tropical waters (mostly from 
Southeast Asia and the Caribbean Sea) and the remaining 16% were recorded from species mostly 
occupying temperate waters (e.g., European countries and Japan).  
Antitumor drugs are the main area of interest in the screening of MNPs from cnidarians   
(41%, Figure 3). This is not surprising, as the major financial effort for the screening of new marine 
compounds is made in cancer research [192]. Terpenoids (terpenoid, diterpenoid, sesquiterpenoid, 
sesterterpenoid, cembranoid) [193] (Figure 4) are the main chemistry group within the MNPs analyzed 
in this survey. 
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Figure 2. Marine bioactive compounds with high biotechnological potential studied from 
the phylum Cnidaria in the last decade. 
 
Figure 3. Distribution in drug classes of marine bioactive compounds with high 
biotechnological potential studied from cnidarian species in the last decade. 
 
Figure 4. Distribution of chemistry classes of marine bioactive compounds with high 
biotechnological potential studied from cnidarian species in the last decade. 
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Even though most pharmaceutical industries abandoned their natural product-based discovery 
programs over a decade ago, the lack of new compounds in their pipelines in some strategic areas  
(e.g., antibiotics) suggests that renewed interest in this field is imminent. The establishment of small 
biotech companies can play a decisive role in the initial discovery of promising marine bioactive 
compounds, as these enterprises will work closely together with academics and governmental agencies 
performing the initial steps in the discovery of new MNPs. Collaboration between private companies 
and public institutions can be of paramount importance for financial support in the discovery process. 
On the other side, crude extracts and pure compounds produced by academic laboratories may be 
screened by diverse bioassays as a part of broader collaboration programs, nationally and 
internationally, with private biotech companies. One challenge for universities is to devise mechanisms 
that protect intellectual property and simultaneously encourage partnerships with the private sector, by 
recognizing that the chances of a major commercial pay-off are small if drug discovery is pursued by a 
single institution [3]. 
The commercial use of some promising marine bioactive compounds isolated from cnidarians may 
be several years away. New compounds other than toxins and venoms produced by members of this 
highly diverse group of marine invertebrates may be discovered in the quest for new marine products. 
Acknowledgements 
Joana Rocha is supported by a Fundação para a Ciência e Tecnologia PhD Grant (SFRH/BD/33476/ 
2008) by PhD Program in Marine and Environmental Sciences. This research was partially financed by 
project LUSOEXTRACT (project no. 13107, QREN-SI I&DT, co-promotion and co-financed by POR 
Lisboa, AdI). The authors would like to acknowledge one anonymous reviewer and Daphne Fautin for 
their valuable comments on the manuscript. 
References 
1.  Jain, R.; Sonawane, S.; Mandrekar, N. Marine organisms: Potential source for drug discovery. 
Curr. Sci. 2008, 94, 292. 
2.  Fenical, W.; Jensen, P.R.; Palladino, M.A.; Lam, K.S.; Lloyd, G.K.; Potts, B.C. Discovery and 
development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 2009, 
17, 2175–2180. 
3.  Hill, R.T.; Fenical, W. Pharmaceuticals from marine natural products: Surge or ebb? Curr. Opin. 
Biotechnol. 2010, 21, 777–779. 
4.  Glaser, K.B.; Mayer, A.M.S. A renaissance in marine pharmacology: From preclinical curiosity 
to clinical reality. Biochem. Pharmacol. 2009, 78, 440–448. 
5.  Fusetani, N. Biotechnological potential of marine natural products. Pure Appl. Chem. 2010, 82, 
17–26. 
6.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1999, 16, 155–198. 
7.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1998, 15, 113–158. 
8.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1997, 14, 259–302. 
9.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1996, 13, 75–125. 
10.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1995, 12, 223–269. Mar. Drugs 2011, 9 
 
1876
11.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1994, 11, 355–395. 
12.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1993, 10, 497–539. 
13.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1991, 8, 97–147. 
14.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1990, 7, 269–309. 
15.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1988, 5, 613–663. 
16.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1987, 4, 539–576. 
17.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 1986, 3, 1–33. 
18.  Faulkner, D.J. Marine pharmacology. Antonie Van Leeuwenhoek 2000, 77, 135–145. 
19.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 2001, 18, 1–49. 
20.  Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 2002, 19, 1–48. 
21.  Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural 
products. Nat. Prod. Rep. 2003, 20, 1–48. 
22.  Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural 
products. Nat. Prod. Rep. 2004, 21, 1–49. 
23.  Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural 
products. Nat. Prod. Rep. 2005, 22, 15–61. 
24.  Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural 
products. Nat. Prod. Rep. 2006, 23, 26–78. 
25.  Blunt, J.W.; Copp, B.R.; Hu, W.P.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine 
natural products. Nat. Prod. Rep. 2007, 24, 31–86. 
26.  Blunt, J.W.; Copp, B.R.; Hu, W.P.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine 
natural products. Nat. Prod. Rep. 2008, 25, 35–94. 
27.  Blunt, J.W.; Copp, B.R.; Hu, W.P.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine 
natural products. Nat. Prod. Rep. 2009, 26, 170–244. 
28.  Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural 
products. Nat. Prod. Rep. 2010, 27, 165–237. 
29.  Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural 
products. Nat. Prod. Rep. 2011, 28, 196–268. 
30.  Mayer, A.; Hamann, M. Marine Pharmacology in 2000: Marine compounds with antibacterial, 
anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antituberculosis, and 
antiviral activities; affecting the cardiovascular, immune, and nervous systems and other 
miscellaneous mechanisms of action. Mar. Biotechnol. 2004, 6, 37–52. 
31.  Mayer, A.M.S.; Hamann, M.T. Marine pharmacology in 2001–2002: Marine compounds with 
anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, 
antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the 
cardiovascular, immune and nervous systems and other miscellaneous mechanisms of action. 
Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2005, 140, 265–286. 
32.  Mayer, A.M.S.; Gustafson, K.R. Marine pharmacology in 2001–2002: Antitumour and cytotoxic 
compounds. Eur. J. Cancer 2004, 40, 2676–2704. 
  Mar. Drugs 2011, 9 
 
1877
33.  Mayer, A.M.S.; Rodríguez, A.D.; Berlinck, R.G.S.; Hamann, M.T. Marine pharmacology in 
2003–2004: Marine compounds with anthelmintic antibacterial, anticoagulant, antifungal,   
anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral 
activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous 
mechanisms of action. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2007, 145, 553–581. 
34.  Mayer, A.M.S.; Gustafson, K.R. Marine pharmacology in 2003–2004: Anti-tumour and 
cytotoxic compounds. Eur. J. Cancer 2006, 42, 2241–2270. 
35.  Mayer, A.M.S.; Rodriguez, A.D.; Berlinck, R.G.S.; Hamann, M.T. Marine pharmacology in 
2005–2006: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal,   
anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting 
the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. 
Biochim. Biophys. Acta Gen. Subj. 2009, 1790, 283–308. 
36.  Mayer, A.M.S.; Gustafson, K.R. Marine pharmacology in 2005–2006: Antitumour and cytotoxic 
compounds. Eur. J. Cancer 2008, 44, 2357–2387. 
37.  Mayer, A.M.S.; Rodríguez, A.D.; Berlinck, R.G.S.; Fusetani, N. Marine pharmacology in   
2007–2008: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, 
antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and 
nervous system, and other miscellaneous mechanisms of action. Comp. Biochem. Physiol. C 
Toxicol. Pharmacol. 2011, 153, 191–222. 
38.  Mayer, A.M.S.; Hamann, M.T. Marine pharmacology in 1999: Compounds with antibacterial, 
anticoagulant, antifungal, anthelmintic, anti-inflammatory, antiplatelet, antiprotozoal and 
antiviral activities affecting the cardiovascular, endocrine, immune and nervous systems, and 
other miscellaneous mechanisms of action. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 
2002, 132, 315–339. 
39.  Sipkema, D.; Franssen, M.C.R.; Osinga, R.; Tramper, J.; Wijffels, R.H. Marine sponges as 
pharmacy. Mar. Biotechnol. 2005, 7, 142–162. 
40.  Newman, D.J.; Cragg, G.M. Marine natural products and related compounds in clinical and 
advanced preclinical trials. J. Nat. Prod. 2004, 67, 1216–1238. 
41.  Turk, T.; Kem, W.R. The phylum Cnidaria and investigations of its toxins and venoms until 
1990. Toxicon 2009, 54, 1031–1037. 
42.  Daly, M.; Brugler, M.R.; Cartwright, P.; Collins, A.G.; Dawson, M.N.; Fautin, D.G.;   
France, S.C.; McFadden, C.S.; Opresko, D.M.; Rodriguez, E.; et al. The phylum Cnidaria: A 
review of phylogenetic patterns and diversity 300 years after Linnaeus. Zootaxa 2007, 1668,  
127–182. 
43.  Boyd, M.R.; Paull, K.D.; Rubinstein, L.R. Data display and analysis strategies for the   
NCI disease-oriented in vitro antitumor drug screen. In Cytotoxic Anticancer Drugs: Models  
and Concepts for Drug Discovery and Development; Springer: Dordrecht, The Netherlands, 
1992; p. 20. 
44.  El-Gamal, A.A.H.; Chiang, C.-Y.; Huang, S.-H.; Wang, S.-K.; Duh, C.-Y. Xenia diterpenoids 
from the Formosan soft coral Xenia blumi. J. Nat. Prod. 2005, 68, 1336–1340. Mar. Drugs 2011, 9 
 
1878
45.  Duh, C.Y.; El-Gamal, A.A.H.; Chu, C.J.; Wang, S.K.; Dai, C.F. New cytotoxic constituents from 
the Formosan soft corals Clavularia viridis and Clavularia violacea. J. Nat. Prod. 2002, 65, 
1535–1539. 
46.  Appeltans, W.; Bouchet, P.; Boxshall, G.A.; Fauchald, K.; Gordon, D.P.; Hoeksema, B.W.; 
Poore, G.C.B.; van Soest, R.W.M.; Stöhr, S.; Walter, T.C.; Costello, M.J. Cnidaria. World 
Register of Marine Species, 2010. Available online: http://www.marinespecies.org/aphia.php? 
p=taxdetails&id=1267 (accessed on 4 January 2011).  
47.  Fautin, D. University of Kansas, Lawrence, KS, USA. Personal communication by e-mail, 2011. 
48.  Strukelj, B.; Lenarcic, B.; Gruden, K.; Pungercar, J.; Rogelj, B.; Turk, V.; Bosch, D.; Jongsma, M.A. 
Equistatin, a protease inhibitor from the sea anemone Actinia equina, is composed of three 
structural and functional domains. Biochem. Biophys. Res. Commun. 2000, 269, 732–736. 
49.  Fontana, A.; Ciavatta, M.L.; Cimino, G. Cladocoran A and B: Two novel γ-hydroxybutenolide 
sesterterpenes from the Mediterranean coral Cladocora cespitosa.  J. Org. Chem. 1998,  63,  
2845–2849. 
50.  Miyaoka, H.; Yamanishi, M.; Mitome, H. PLA2 inhibitory activity of marine sesterterpenoids 
cladocorans, their diastereomers and analogues. Chem. Pharm. Bull. 2006, 54, 268–270. 
51.  Meyer, M.; Delberghe, F.; Liron, F.; Guillaume, M.; Valentin, A.; Guyot, M. An antiplasmodial 
new (bis)indole alkaloid from the hard coral Tubastraea sp. Nat. Prod. Res. 2009, 23, 178–182. 
52.  Hooper, G.J.; Davies-Coleman, M.T. New metabolites from the South African soft coral 
Capnella thyrsoidea. Tetrahedron 1995, 51, 9973–9984. 
53.  Bhakuni, D.S.; Rawat, D.S. Bioactive Marine Natural Products; Springer: Dordrecht, The 
Netherlands, 2005; p. 396. 
54.  Wu, S.L.; Su, J.H.; Wen, Z.H.; Hsu, C.H.; Chen, B.W.; Dai, C.F.; Kuo, Y.H.; Sheu, J.H. 
Simplexins A–I, eunicellin-based diterpenoids from the soft coral Klyxum simplex. J. Nat. Prod. 
2009, 72, 994–1000. 
55.  Chen, B.W.; Wu, Y.C.; Chiang, M.Y.; Su, J.H.; Wang, W.H.; Fan, T.Y.; Sheu, J.H.   
Eunicellin-based diterpenoids from the cultured soft coral Klyxum simplex. Tetrahedron 2009, 
65, 7016–7022. 
56.  Nguyen, H.T.; Chau, V.M.; Phan, V.K.; Hoang, T.H.; Nguyen, H.N.; Nguyen, X.C.; Tran, H.Q.; 
Nguyen, X.N.; Hyun, J.H.; Kang, H.K.; et al. Chemical components from the Vietnamese soft 
coral Lobophytum sp. Arch. Pharm. Res. 2010, 33, 503–508. 
57.  Rashid, M.A.; Gustafson, K.R.; Boyd, M.R. HIV-inhibitory cembrane derivatives from a 
Philippines collection of the soft coral Lobophytum species. J. Nat. Prod. 2000, 63, 531–533. 
58.  Chao, C.-H.; Wen, Z.-H.; Wu, Y.-C.; Yeh, H.-C.; Sheu, J.-H. Cytotoxic and anti-inflammatory 
cembranoids from the soft coral Lobophytum crassum. J. Nat. Prod. 2008, 71, 1819–1824. 
59.  Coval, S.J.; Patton, R.W.; Petrin, J.M.; James, L.; Rothofsky, M.L.; Lin, S.L.; Patel, M.;   
Reed, J.K.; McPhail, A.T.; Bishop, W.R. A cembranolide diterpene farnesyl protein transferase 
inhibitor from the marine soft coral Lobophytum cristagalli. Bioorg. Med. Chem. Lett. 1996, 6, 
909–912. 
60.  Cheng, S.-Y.; Wen, Z.-H.; Chiou, S.-F.; Hsu, C.-H.; Wang, S.-K.; Dai, C.-F.; Chiang, M.Y.; 
Duh, C.-Y. Durumolides A–E, anti-inflammatory and antibacterial cembranolides from the soft 
coral Lobophytum durum. Tetrahedron 2008, 64, 9698–9704. Mar. Drugs 2011, 9 
 
1879
61.  Cheng, S.Y.; Wen, Z.H.; Wang, S.K.; Chiou, S.F.; Hsu, C.H.; Dai, C.F.; Chiang, M.Y.;   
Duh, C.Y. Unprecedented hemiketal cembranolides with anti-inflammatory activity from the soft 
coral Lobophytum durum. J. Nat. Prod. 2009, 72, 152–155. 
62.  Huang, H.C.; Chao, C.H.; Kuo, Y.H.; Sheu, J.H. Crassocolides G–M, cembranoids from the 
Formosan soft coral Sarcophyton crassocaule. Chem. Biodivers. 2009, 6, 1232–1242. 
63.  Fusetani, N. Research toward drugs from the sea. New J. Chem. 1990, 14, 721–728. 
64.  Dmitrenok, A.S.; Radhika, P.; Anjaneyulu, V.; Subrahmanyam, C.; Subba Rao, P.V.;   
Dmitrenok, P.S.; Boguslavsky, V.M. New lipids from the soft corals of the Andaman Islands. 
Russ. Chem. Bull. 2003, 52, 1868–1872. 
65.  Lin, Y.S.; Chen, C.H.; Liaw, C.C.; Chen, Y.C.; Kuo, Y.H.; Shen, Y.C. Cembrane diterpenoids 
from the Taiwanese soft coral Sinularia flexibilis. Tetrahedron 2009, 65, 9157–9164. 
66.  Michalek, K.; Bowden, B.F. A natural algacide from soft coral Sinularia flexibilis (Coelenterata, 
Octocorallia, Alcyonacea). J. Chem. Ecol. 1997, 23, 259–273. 
67.  Ahmed, A.F.; Hsieh, Y.-T.; Wen, Z.-H.; Wu, Y.-C.; Sheu, J.-H. Polyoxygenated sterols from the 
Formosan soft coral Sinularia gibberosa. J. Nat. Prod. 2006, 69, 1275–1279. 
68.  Lu, Y.; Huang, C.Y.; Lin, Y.F.; Wen, Z.H.; Su, J.H.; Kuo, Y.H.; Chiang, M.Y.; Sheu, J.H.  
Anti-inflammatory cembranoids from the soft corals Sinularia querciformis and Sinularia granosa. 
J. Nat. Prod. 2008, 71, 1754–1759. 
69.  Yabe, T.; Yamada, H.; Shimomura, M.; Miyaoka, H.; Yamada, Y. Induction of choline 
acetyltransferase activity in cholinergic neurons by stolonidiol: structure-activity relationship.  
J. Nat. Prod. 2000, 63, 433–435. 
70.  Iwashima, M.; Matsumoto, Y.; Takahashi, H.; Iguchi, K. New marine cembrane-type diterpenoids 
from the Okinawan soft coral Clavularia koellikeri. J. Nat. Prod. 2000, 63, 1647–1652. 
71.  Lin, Y.S.; Khalil, A.T.; Chiou, S.H.; Kuo, Y.C.; Cheng, Y.B.; Liaw, C.C.; Shen, Y.C. Bioactive 
marine prostanoids from octocoral Clavularia viridis. Chem. Biodivers. 2008, 5, 784–792. 
72.  Watanabe, K.; Sekine, M.; Takahashi, H.; Iguchi, K. New halogenated marine prostanoids   
with cytotoxic activity from the Okinawan soft coral Clavularia viridis. J. Nat. Prod. 2001, 64,  
1421–1425. 
73.  Shen, Y.C.; Cheng, Y.B.; Lin, Y.C.; Guh, J.H.; Teng, C.M.; Ko, C.L. New prostanoids with 
cytotoxic activity from Taiwanese octocoral Clavularia viridis. J. Nat. Prod. 2004, 67, 542–546. 
74.  Chiang, P.-C.; Chien, C.-L.; Pan, S.-L.; Chen, W.-P.; Teng, C.-M.; Shen, Y.-C.; Guh, J.-H. 
Induction of endoplasmic reticulum stress and apoptosis by a marine prostanoid in human 
hepatocellular carcinoma. J. Hepatol. 2005, 43, 679–686. 
75.  Iwashima, M.; Nara, K.; Nakamichi, Y.; Iguchi, K. Three new chlorinated marine steroids, 
yonarasterols G, H and I, isolated from the Okinawan soft coral Clavularia viridis. Steroids 
2001, 66, 25–32. 
76.  Verbitski, S.M.; Mullally, J.E.; Fitzpatrick, F.A.; Ireland, C.M. Punaglandins, chlorinated 
prostaglandins, function as potent Michael receptors to inhibit ubiquitin isopeptidase activity.  
J. Med. Chem. 2004, 47, 2062–2070. 
77.  Tomono, Y.; Hirota, H.; Fusetani, N. Isogosterones A–D, antifouling 13,17-Secosteroids from an 
octocoral Dendronephthya sp. J. Org. Chem. 1999, 64, 2272–2275. Mar. Drugs 2011, 9 
 
1880
78.  Grote, D.; Hanel, F.; Dahse, H.M.; Seifert, K. Capnellenes from the soft coral Dendronephthya 
rubeola. Chem. Biodivers. 2008, 5, 1683–1693. 
79.  Peukert, K.; Staller, P.; Schneider, A.; Carmichael, G.; Hanel, F.; Eilers, M. An alternative 
pathway for gene regulation by Myc. EMBO J. 1997, 16, 5672–5686. 
80.  Hermeking, H. The MYC oncogene as a cancer drug target. Curr. Cancer Drug Targets 2003, 3, 
163–175. 
81.  Cheng, S.Y.; Huang, K.J.; Wang, S.K.; Wen, Z.H.; Hsu, C.H.; Dai, C.F.; Duh, C.Y. New 
terpenoids from the soft corals Sinularia capillosa and Nephthea chabroli. Org. Lett. 2009, 11, 
4830–4833. 
82.  Cheng, S.Y.; Wen, Z.H.; Wang, S.K.; Chiang, M.Y.; El-Gamal, A.A.H.; Dai, C.F.; Duh, C.Y. 
Revision of the absolute configuration at C(23) of Lanostanoids and isolation of secondary 
metabolites from Formosan soft coral Nephthea erecta. Chem. Biodivers. 2009, 6, 86–95. 
83.  Lin, Y.C.; Abd El-Razek, M.H.; Hwang, T.L.; Chiang, M.Y.; Kuo, Y.H.; Dai, C.F.; Shen, Y.C. 
Asterolaurins A–F, xenicane diterpenoids from the Taiwanese soft coral Asterospicularia laurae. 
J. Nat. Prod. 2009, 72, 1911–1916. 
84.  Duh, C.-Y.; El-Gamal, A.A.H.; Wang, S.-K.; Dai, C.-F. Novel terpenoids from the Formosan 
soft coral Cespitularia hypotentaculata. J. Nat. Prod. 2002, 65, 1429–1433. 
85.  Bishara, A.; Rudi, A.; Goldberg, I.; Benayahu, Y.; Kashman, Y. Novaxenicins A–D and 
xeniolides I–K, seven new diterpenes from the soft coral Xenia novaebrittanniae. Tetrahedron 
2006, 62, 12092–12097. 
86.  Konig, G.M.; Wright, A.D. New cembranoid diterpenes from the soft coral Sarcophyton 
ehrenbergi. J. Nat. Prod. 1998, 61, 494–496. 
87.  Chang, C.H.; Wen, Z.H.; Wang, S.K.; Duh, C.Y. Capnellenes from the Formosan soft coral 
Capnella imbricata. J. Nat. Prod. 2008, 71, 619–621. 
88.  Duh, C.Y.; Hou, R.S. Cytotoxic cembranoids from the soft corals Sinularia gibberosa and 
Sarcophyton trocheliophorum. J. Nat. Prod. 1996, 59, 595–598. 
89.  Su, J.H.; Ahmed, A.F.; Sung, P.J.; Chao, C.H.; Kuo, Y.H.; Sheu, J.H. Manaarenolides A–I, 
diterpenoids from the soft coral Sinularia manaarensis. J. Nat. Prod. 2006, 69, 1134–1139. 
90.  Norton, R.S.; Kazlauskas, R. C-13 NMR-study of flexibilide, an anti-inflammatory agent from a 
soft coral. Experientia 1980, 36, 276–278. 
91.  Williams, D.H.; Faulkner, D.J. Two practical syntheses of an anti-inflammatory sesquiterpene 
furoic acid from Sinularia spp. Tetrahedron 1996, 52, 4245–4256. 
92.  Weinheimer, A.J.; Matson, J.A.; Hossain, M.B.; van der Helm, D. Marine anticancer agents: 
sinularin and dihydrosinularin, new cembranolides from the soft coral Sinularia flexibilis. 
Tetrahedron Lett. 1977, 18, 2923–2926. 
93.  Li, G.Q.; Zhang, Y.L.; Deng, Z.W.; van Ofwegen, L.P.; Proksch, P.; Lin, W.H. Cytotoxic 
cembranoid Diterpenes from a soft coral Sinularia gibberosa. J. Nat. Prod. 2005, 68, 649–652. 
94.  Aceret, T.L.; Coll, J.C.; Uchio, Y.; Sammarco, P.W. Antimicrobial activity of the diterpenes 
flexibilide and sinulariolide derived from Sinularia flexibilis Quoy and Gaimard 1833 
(Coelenterata: Alcyonacea, Octocorallia). Comp. Biochem. Physiol. C Pharmacol. Toxicol. 
Endocrinol. 1998, 120, 121–126. Mar. Drugs 2011, 9 
 
1881
95.  Aceret, T.L.; Brown, L.; Miller, J.; Coll, J.C.; Sammarco, P.W. Cardiac and vascular responses 
of isolated rat tissues treated with diterpenes from Sinularia flexibilis (Coelenterata: 
Octocorallia). Toxicon 1996, 34, 1165–1171. 
96.  Sheikh, Y.M.; Singy, G.; Kaisin, M.; Eggert, H.; Djerassi, C.; Tursch, B.; Daloze, D.;   
Braekman, J.C. Terpenoids—LXXI: Chemical studies of marine invertebrates-XIV. Four 
representatives of a novel sesquiterpene class—the capnellane skeleton. Tetrahedron 1976, 32, 
1171–1178. 
97.  Kaisin, M.; Sheikh, Y.M.; Durham, L.J.; Djerassi, C.; Tursch, B.; Daloze, D.; Braekman, J.C.; 
Losman, D.; Karlsson, R. Capnellane—a new tricyclic sesquiterpene skeleton from the soft coral 
Capnella imbricata. Tetrahedron Lett. 1974, 15, 2239–2242. 
98.  Kaisin, M.; Braekman, J.C.; Daloze, D.; Tursch, B. Novel acetoxycapnellenes from the 
alcyonacean Capnella imbricata. Tetrahedron 1985, 41, 1067–1072. 
99.  Nakao, Y.; Fusetani, N. Enzyme inhibitors from marine invertebrates. J. Nat. Prod. 2007, 70, 
689–710. 
100.  Sata, N.U.; Sugano, M.; Matsunaga, S.; Fusetani, N. Sinulamide: An H,K-ATPase inhibitor from 
a soft coral Sinularia sp. Tetrahedron Lett. 1999, 40, 719–722. 
101. Huang, H.-C.; Wen, Z.-H.; Chao, C.-H.; Ahmed, A.F.; Chiang, M.Y.; Kuo, Y.-H.; Hsu, C.-H.; 
Sheu, J.-H. Novel sesquiterpenoids from the Formosan soft coral Paralemnalia thyrsoides. 
Tetrahedron Lett. 2006, 47, 8751–8755. 
102. Coll, J.C. The chemistry and chemical ecology of octocorals (Coelenterata, Anthozoa, 
Octocorallia). Chem. Rev. 1992, 92, 613–631. 
103. Maida, M.; Sammarco, P.W.; Coll, J.C. A diffusion chamber for assessing efficacy of natural 
anti-fouling defenses in marine organisms. J. Exp. Mar. Biol. Ecol. 2006, 337, 59–64. 
104. Chambers, L.D.; Stokes, K.R.; Walsh, F.C.; Wood, R.J.K. Modern approaches to marine 
antifouling coatings. Surf. Coat. Technol. 2006, 201, 3642–3652. 
105. Watanabe, K.; Iwashima, M.; Iguchi, K. New marine prostanoid carboxylate salts from the 
Okinawan soft coral Clavularia viridis. J. Nat. Prod. 1996, 59, 980–982. 
106.  Iwashima, M.; Terada, I.; Okamoto, K.; Iguchi, K. Tricycloclavulone and clavubicyclone, novel 
prostanoid-related marine oxylipins, isolated from the Okinawan soft coral Clavularia viridis.  
J. Org. Chem. 2002, 67, 2977–2981. 
107. Kusumi, T.; Hamada, T.; Hara, M.; Ishitsuka, M.O.; Ginda, H.; Kakisawa, H. Structure and 
absolute-configuration of Isoclavukerin-A, a component from an Okinawan soft coral. 
Tetrahedron Lett. 1992, 33, 2019–2022. 
108.  Davies, P.; Maloney, A.J.F. Selective loss of central cholinergic neurons in Alzheimer’s disease. 
Lancet 1976, 308, 1403–1403. 
109. Whitehouse, P.; Price, D.; Struble, R.; Clark, A.; Coyle, J.; Delon, M. Alzheimer’s disease and 
senile dementia: Loss of neurons in the basal forebrain. Science 1982, 215, 1237–1239. 
110. Bartus, R.; Dean, R.; Beer, B.; Lippa, A. The cholinergic hypothesis of geriatric memory 
dysfunction. Science 1982, 217, 408–414. 
111. Chiang, P.C.; Kung, F.L.; Huang, D.M.; Li, T.K.; Fan, J.R.; Pan, S.L.; Shen, Y.C.; Guh, J.H. 
Induction of Fas clustering and apoptosis by coral prostanoid in human hormone-resistant 
prostate cancer cells. Eur. J. Pharmacol. 2006, 542, 22–30. Mar. Drugs 2011, 9 
 
1882
112.  Tsukamoto, S.; Yokosawa, H. Inhibition of the ubiquitin-proteasome system by natural products 
for cancer therapy. Planta Med. 2010, 76, 1064–1074. 
113. Chai, X.Y.; Sun, J.F.; Tang, L.Y.; Yang, X.W.; Li, Y.Q.; Huang, H.; Zhou, X.F.; Yang, B.;  
Liu, Y.H. A novel cyclopentene derivative and a polyhydroxylated steroid from a South China 
sea gorgonian Menella sp. Chem. Pharm. Bull. 2010, 58, 1391–1394. 
114. Sheu, J.-H.; Hung, K.-C.; Wang, G.-H.; Duh, C.-Y. New Cytotoxic Sesquiterpenes from the 
Gorgonian Isis hippuris. J. Nat. Prod. 2000, 63, 1603–1607. 
115. González, N.; Barral, M.A.; Rodríguez, J.; Jiménez, C. New cytotoxic steroids from the 
gorgonian Isis hippuris. Structure-activity studies. Tetrahedron 2001, 57, 3487–3497. 
116.  Sheu, J.H.; Chao, C.H.; Wang, G.H.; Hung, K.C.; Duh, C.Y.; Chiang, M.Y.; Wu, Y.C.; Wu, C.C. 
The first A-nor-hippuristanol and two novel 4,5-secosuberosanoids from the Gorgonian   
Isis hippuris. Tetrahedron Lett. 2004, 45, 6413–6416. 
117. Chao, C.-H.; Huang, L.-F.; Yang, Y.-L.; Su, J.-H.; Wang, G.-H.; Chiang, M.Y.; Wu, Y.-C.;  
Dai, C.-F.; Sheu, J.-H. Polyoxygenated steroids from the gorgonian Isis hippuris. J. Nat. Prod. 
2005, 68, 880–885. 
118.  Sung, P.-J.; Chen, Y.-P.; Hwang, T.-L.; Hu, W.-P.; Fang, L.-S.; Wu, Y.-C.; Li, J.-J.; Sheu, J.-H. 
Briaexcavatins C–F, four new briarane-related diterpenoids from the Formosan octocoral 
Briareum excavatum (Briareidae). Tetrahedron 2006, 62, 5686–5691. 
119. Sung, P.-J.; Su, J.-H.; Duh, C.-Y.; Chiang, M.Y.; Sheu, J.-H. Briaexcavatolides K–N, new 
briarane diterpenes from the Gorgonian Briareum excavatum. J. Nat. Prod. 2001, 64, 318–323. 
120.  Ospina, C.A.; Rodríguez, A.D.; Ortega-Barria, E.; Capson, T.L. Briarellins J–P and Polyanthellin A: 
New Eunicellin-based diterpenes from the gorgonian coral Briareum polyanthes and their 
antimalarial activity. J. Nat. Prod. 2003, 66, 357–363. 
121. Shen, Y.C.; Chen, Y.H.; Hwang, T.L.; Guh, J.H.; Khalil, A.T. Four new briarane diterpenoids 
from the gorgonian coral Junceella fragilis. Helv. Chim. Acta 2007, 90, 1391–1398. 
122.  Qi, S.H.; Zhang, S.; Qian, P.Y.; Xu, H.H. Antifeedant and antifouling briaranes from the South 
China Sea gorgonian Junceella juncea. Chem. Nat. Compd. 2009, 45, 49–54. 
123.  Targett, N.M.; Bishop, S.S.; McConnell, O.J.; Yoder, J.A. Antifouling agents against the benthic 
marine diatom Navicula salinicola: Homarine from the gorgonians Leptogorgia virgulata and  
L. setacea and analogs. J. Chem. Ecol. 1983, 9, 817–829. 
124. Gerhart, D.J.; Rittschof, D.; Mayo, S.W. Chemical ecology and the search for marine 
antifoulants—Studies of a predatory-prey symbiosis. J. Chem. Ecol. 1988, 14, 1905–1917. 
125. He, H.Y.; Kulanthaivel, P.; Baker, B.J.; Kalter, K.; Darges, J.; Cofield, D.; Wolff, L.;   
Adams, L. New antiproliferative and antiinflammatory 9,11-secosterols from the gorgonian 
Pseudopterogorgia sp. Tetrahedron 1995, 51, 51–58. 
126. Kate, A.S.; Pearson, J.K.; Ramanathan, B.; Richard, K.; Kerr, R.G. Isolation, biomimetic 
synthesis, and cytotoxic activity of bis(pseudopterane) amines. J. Nat. Prod. 2009, 72, 1331–1334. 
127. Ospina, C.A.; Rodríguez, A.D.; Zhao, H.; Raptis, R.G. Bipinnapterolide B, a bioactive 
oxapolycyclic diterpene from the Colombian gorgonian coral Pseudopterogorgia bipinnata. 
Tetrahedron Lett. 2007, 48, 7520–7523. Mar. Drugs 2011, 9 
 
1883
128. Ospina, C.A.; Rodríguez, A.D.; Sánchez, J.A.; Ortega-Barria, E.; Capson, T.L.; Mayer, A.M.S. 
Caucanolides A–F, unusual antiplasmodial constituents from a Colombian collection of the 
gorgonian coral Pseudopterogorgia bipinnata. J. Nat. Prod. 2005, 68, 1519–1526. 
129. Ata, A.; Win, H.Y.; Holt, D.; Holloway, P.; Segstro, E.P.; Jayatilake, G.S. New antibacterial 
diterpenes from Pseudopterogorgia elisabethae. Helv. Chim. Acta 2004, 87, 1090–1098. 
130. Rodríguez, I.I.; Rodríguez, A.D.; Wang, Y.; Franzblau, S.G. Ileabethoxazole: A novel 
benzoxazole alkaloid with antimycobacterial activity. Tetrahedron Lett. 2006, 47, 3229–3232. 
131. Rodríguez, I.I.; Rodríguez, A.D. Homopseudopteroxazole, a new antimycobacterial diterpene 
alkaloid from Pseudopterogorgia elisabethae. J. Nat. Prod. 2003, 66, 855–857. 
132. Wei, X.; Rodríguez, I.I.; Rodríguez, A.D.; Barnes, C.L. Caribenols A and B, sea whip derived 
norditerpenes with novel tricarbocyclic skeletons. J. Org. Chem. 2007, 72, 7386–7389. 
133. Rodriguez, A.D.; Ramirez, C.; Rodriguez, II; Barnes, C.L. Novel terpenoids from the West 
Indian sea whip Pseudopterogorgia elisabethae (Bayer). Elisapterosins A and B: Rearranged 
diterpenes possessing an unprecedented cagelike framework. J. Org. Chem. 2000, 65, 1390–1398. 
134. Rodriguez, I.I.; Rodriguez, A.D.; Zhao, H. Aberrarone: A gorgonian-derived diterpene from 
Pseudopterogorgia elisabethae. J. Org. Chem. 2009, 74, 7581–7584. 
135. Marrero, J.; Rodríguez, A.D.; Baran, P.; Raptis, R.G.; Sánchez, J.A.; Ortega-Barria, E.;   
Capson, T.L. Bielschowskysin, a gorgonian-derived biologically active diterpene with an 
unprecedented carbon skeleton. Org. Lett. 2004, 6, 1661–1664. 
136.  McEnroe, F.J.; Fenical, W. Structures and synthesis of some new antibacterial sesquiterpenoids 
from the gorgonian coral Pseudopterogorgia rigida. Tetrahedron 1978, 34, 1661–1664. 
137. Garzón, S.P.; Rodríguez, A.D.; Sánchez, J.A.; Ortega-Barria, E. Sesquiterpenoid metabolites 
with antiplasmodial activity from a Caribbean gorgonian coral Eunicea sp. J. Nat. Prod. 2005, 
68, 1354–1359. 
138. Shin, J.H.; Fenical, W. Fuscosides A–D: Antinflammatory diterpenoid glycosides of new 
structural classes from the Caribbean gorgonian Eunicea fusca. J. Org. Chem. 1991, 56, 3153–3158. 
139. Kikuchi, H.; Tsukitani, Y.; Nakanishi, H.; Shimizu, I.; Saitoh, S.; Iguchi, K.; Yamada, Y. New 
butenolides from the gorgonian Euplexaura flava (Nutting). Chem. Lett. 1982, 11, 233–236. 
140. Rodríguez, A.D. The natural products chemistry of West Indian gorgonian octocorals. 
Tetrahedron 1995, 51, 4571–4618. 
141. Fenical, W. Marine soft corals of the genus Pseudopterogorgia: A resource for novel   
anti-inflammatory diterpenoids. J. Nat. Prod. 1987, 50, 1001–1008. 
142.  Marrero, J.; Ospina, C.A.; Rodríguez, A.D.; Baran, P.; Zhao, H.; Franzblau, S.G.; Ortega-Barria, E. 
New diterpenes of the pseudopterane class from two closely related Pseudopterogorgia species: 
Isolation, structural elucidation, and biological evaluation. Tetrahedron 2006, 62, 6998–7008. 
143. Martelletti, P.; Adriani, E.; Bonini, S.; Celestino, D.; Lenti, L.; Armaleo, C.; Dipastena, A.; 
Misasi, R.; Giacovazzo, M. Basophil histamine-release and Leukotriene (LTB4-LTC4) 
production in cluster headache. Headache 1989, 29, 46–48. 
144. Jacobson, P.B.; Jacobs, R.S. Fuscoside—An antiinflammatory marine natural product which 
selectively inhibits 5-lipoxygenase. Biochemical-studies in the human neutrophil. J. Pharmacol. 
Exp. Ther. 1992, 262, 874–882. Mar. Drugs 2011, 9 
 
1884
145.  Nathan, C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 2006, 6, 
173–182. 
146. Lacy, P.; Eitzen, G. Control of granule exocytosis in neutrophils. Front. Biosci. 2008,  13,  
5559–5570. 
147. Pham, C.T.N. Neutrophil serine proteases: specific regulators of inflammation. Nat. Rev. 
Immunol. 2006, 6, 541–550. 
148. Boukouvalas, J.; Loach, R.P. General, regiodefined access to alpha-substituted butenolides 
through metal-halogen exchange of 3-bromo-2-silyloxyfurans. Efficient synthesis of an   
anti-inflammatory gorgonian lipid. J. Org. Chem. 2008, 73, 8109–8112. 
149. Sung, P.J.; Sheu, J.H.; Xu, J.P. Survey of briarane-type diterpenoids of marine origin. 
Heterocycles 2002, 57, 535–579. 
150. Sung, P.J.; Chang, P.C.; Fang, L.S.; Sheu, J.H.; Chen, W.C.; Chen, Y.P.; Lin, M.R. Survey of 
briarane-related diterpenoids—part II. Heterocycles 2005, 65, 195–204. 
151. Wu, S.L.; Sung, P.J.; Chiang, M.Y.; Wu, J.Y.; Sheu, J.H. New polyoxygenated briarane 
diterpenoids, Briaexcavatolides O–R, from the Gorgonian Briareum excavatum. J. Nat. Prod. 
2001, 64, 1415–1420. 
152.  Lenarcic, B.; Ritonja, A.; Strukelj, B.; Turk, B.; Turk, V. Equistatin, a new inhibitor of cysteine 
proteinases from Actinia equina, is structurally related to thyroglobulin type-1 domain. J. Biol. 
Chem. 1997, 272, 13899–13903. 
153. Lenarcic, B.; Turk, V. Thyroglobulin Type-1 domains in equistatin inhibit both Papain-like 
cysteine proteinases and Cathepsin D. J. Biol. Chem. 1999, 274, 563–566. 
154. Brömme, D.; Petanceska, S. Papain-Like Cysteine Proteases and Their Implications in 
Neurodegenerative Diseases. In Role of Proteases in the Pathophysiology of Neurodegenerative 
Diseases; Lajtha, A., Banik, N.L., Eds.; Springer: New York, NY, USA, 2002; pp. 47–61. 
155. Wolf, M.; Clark-Lewis, I.; Buri, C.; Langen, H.; Lis, M.; Mazzucchelli, L. Cathepsin D 
specifically cleaves the chemokines macrophage inflammatory protein-la, macrophage 
inflammatory protein-1 beta, and SLC that are expressed in human breast cancer. Am. J. Pathol. 
2003, 162, 1183–1190. 
156. NCBI. CTSD cathepsin D [Homo sapiens] In Entrez Gene—Genes and mapped phenotypes: 
2010. Available online: http://www.ncbi.nlm.nih.gov/gene/1509 (accessed on 7 December 2010). 
157.  Muller, A.J.; DuHadaway, J.B.; Donover, P.S.; Sutanto-Ward, E.; Prendergast, G.C. Inhibition of 
indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, 
potentiates cancer chemotherapy. Nat. Med. 2005, 11, 312–319. 
158.  Grohmann, U.; Fallarino, F.; Puccetti, P. Tolerance, DCs and tryptophan: much ado about IDO. 
Trends Immunol. 2003, 24, 242–248. 
159.  Pereira, A.; Vottero, E.; Roberge, M.; Mauk, A.G.; Andersen, R.J. Indoleamine 2,3-dioxygenase 
inhibitors from the northeastern Pacific marine hydroid Garveia annulata. J. Nat. Prod. 2006, 
69, 1496–1499. 
160. Muller, A.J.; Malachowski, W.P.; Prendergast, G.C. Indoleamine 2,3-dioxygenase in cancer: 
Targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin. Ther. 
Targets 2005, 9, 831–849. Mar. Drugs 2011, 9 
 
1885
161.  Seo, Y.W.; Cho, K.W.; Rho, J.R.; Shin, J.H.; Kwon, B.M.; Bok, S.H.; Song, J.I.   
Solandelactones A–I, lactonized cyclopropyl oxylipins isolated from the hydroid   
Solanderia secunda. Tetrahedron 1996, 52, 10583–10596. 
162.  Ovchinnikova, T.V.; Balandin, S.V.; Aleshina, G.M.; Tagaev, A.A.; Leonova, Y.F.; 
Krasnodembsky, E.D.; Men’shenin, A.V.; Kokryakov, V.N. Aurelin, a novel antimicrobial 
peptide from jellyfish Aurelia aurita with structural features of defensins and channel-blocking 
toxins. Biochem. Biophys. Res. Commun. 2006, 348, 514–523. 
163. Brinkman, D.L.; Burnell, J.N. Biochemical and molecular characterisation of cubozoan protein 
toxins. Toxicon 2009, 54, 1162–1173. 
164. Synnes, M. Bioprospecting of organisms from the deep sea: Scientific and environmental 
aspects. Clean Technol. Environ. Policy 2007, 9, 53–59. 
165. Moura, C.J.; Cunha, M.R.; Schuchert, P. Tubiclavoides striatum gen. nov et sp nov (Cnidaria: 
Hydrozoa) a new bathyal hydroid from the Gulf of Cadiz, north-east Atlantic Ocean. J. Mar. 
Biol. Assoc. UK 2007, 87, 421–428. 
166. Rodriguez, E.; Lopez-Gonzalez, P.J.; Daly, M. New family of sea anemones (Actiniaria, 
Acontiaria) from deep polar seas. Polar Biol. 2009, 32, 703–717. 
167.  Census of Marine Life. Available online: http://www.coml.org/discoveries/species/ 
bathyal_hydroid (accessed on 3 January 2011). 
168. Fautin, D.G. Structural diversity, systematics, and evolution of cnidae. Toxicon  2009,  54,  
1054–1064. 
169. Clark, M.R.; Tittensor, D.; Rogers, A.D.; Brewin, P.; Schlacher, T.; Rowden, A.; Stocks, K.; 
Consalvey, M. Seamounts, Deep-sea Corals and Fisheries: Vulnerability of Deep-Sea Corals to 
Fishing on Seamounts Beyond Areas of National Jurisdiction; UNEP-WCMC: Cambridge,   
UK, 2006. 
170. Rodriguez, E.; Daly, M. Phylogenetic relationships among deep-sea and chemosynthetic sea 
anemones: Actinoscyphiidae and actinostolidae (Actiniaria: Mesomyaria). PLoS One 2010,  
5, e10958. 
171.  Skropeta, D. Deep-sea natural products. Nat. Prod. Rep. 2008, 25, 1131–1166. 
172. Kingston, D.G.I. Modern natural products drug discovery and its relevance to biodiversity 
conservation. J. Nat. Prod. 2010, 74, 496–511. 
173. Wabnitz, C.; Taylor, M.; Green, E.; Razak, T. From Ocean to Aquarium; UNEP-WCMC: 
Cambridge, UK, 2003. 
174.  White, R.E. High-throughput screening in drug metabolism and pharmacokinetic support of drug 
discovery. Ann. Rev. Pharmacol. Toxicol. 2000, 40, 133–157. 
175. Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. Nat. Rev. 
Drug Discov. 2005, 4, 206–220. 
176. Li, J.W.H.; Vederas, J.C. Drug discovery and natural products: End of an Era or an endless 
frontier? Science 2009, 325, 161–165. 
177. Shafir, S.; Van Rijn, J.; Rinkevich, B. Coral nubbins as source material for coral biological 
research: A prospectus. Aquaculture 2006, 259, 444–448. Mar. Drugs 2011, 9 
 
1886
178. Sella, I.; Benayahu, Y. Rearing cuttings of the soft coral Sarcophyton glaucum (Octocorallia, 
Alcyonacea): Towards mass production in a closed seawater system. Aquaculture Res. 2010, 41, 
1748–1758. 
179.  Qian, P.Y.; Xu, Y.; Fusetani, N. Natural products as antifouling compounds: recent progress and 
future perspectives. Biofouling 2010, 26, 223–234. 
180. Mendola, D. Aquaculture of three phyla of marine invertebrates to yield bioactive metabolites: 
process developments and economics. Biomol. Eng. 2003, 20, 441–458. 
181. Paterson, I.; Anderson, E.A. The renaissance of natural products as drug candidates. Science 
2005, 310, 451–453. 
182.  Khosla, C.; Keasling, J.D. Timeline—Metabolic engineering for drug discovery and development. 
Nat. Rev. Drug Discov. 2003, 2, 1019–1025. 
183.  Piel, J. Metabolites from symbiotic bacteria. Nat. Prod. Rep. 2009, 26, 338–362. 
184.  Piel, J. Metabolites from symbiotic bacteria. Nat. Prod. Rep. 2004, 21, 519–538. 
185. Shimomura, O.; Johnson, F.H.; Saiga, Y. Extraction, purification and properties of aequorin, a 
bioluminescent protein from luminous hydromedusan, Aequorea. J. Cell. Comp. Physiol. 1962, 
59, 223–239. 
186. Schnitzler, C.; Keenan, R.; McCord, R.; Matysik, A.; Christianson, L.; Haddock, S. Spectral 
diversity of fluorescent proteins from the Anthozoan Corynactis californica. Mar. Biotechnol. 
2008, 10, 328–342. 
187. Ip, D.T.M.; Wong, K.B.; Wan, D.C.C. Characterization of novel orange fluorescent protein 
cloned from cnidarian tube anemone Cerianthus sp. Mar. Biotechnol. 2007, 9, 469–478. 
188. Chan, M.C.Y.; Karasawa, S.; Mizuno, H.; Bosanac, I.; Ho, D.; Prive, G.G.; Miyawaki, A.;   
Ikura, M. Structural characterization of a blue chromoprotein and its yellow mutant from the sea 
anemone Cnidopus japonicus. J. Biol. Chem. 2006, 281, 37813–37819. 
189.  Ai, H.W.; Henderson, J.N.; Remington, S.J.; Campbell, R.E. Directed evolution of a monomeric, 
bright and photostable version of Clavularia cyan fluorescent protein: Structural characterization 
and applications in fluorescence imaging. Biochem. J. 2006, 400, 531–540. 
190. Goulding, A.; Shrestha, S.; Dria, K.; Hunt, E.; Deo, S.K. Red fluorescent protein variants with 
incorporated non-natural amino acid analogues. Protein Eng. Des. Sel. 2008, 21, 101–106. 
191.  Tu, H.B.; Xiong, Q.; Zhen, S.L.; Zhong, X.F.; Peng, L.H.; Chen, H.P.; Jiang, X.Y.; Liu, W.H.; 
Yang, W.L.; Wei, J.W.; Dong, M.L.; Wu, W.Y.; Xu, A.L. A naturally enhanced green 
fluorescent protein from magnificent sea anemone (Heteractis magnifica) and its functional 
analysis. Biochem. Biophys. Res. Commun. 2003, 301, 879–885. 
192.  Pomponi, S.A. The oceans and Human health: The discovery and development of marine-derived 
drugs. Oceanography 2001, 14, 78–87. 
193.  Blunt, J.W.; Munro, M.H.G. Dictionary of Marine Natural Products with CD-ROM; Chapman & 
Hall/CRC, Taylor & Francis Group: Boca Raton, FL, USA, 2008; p. 119. 
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 